Work

Cytochrome P450 2C9 Variants Influence Response to Celecoxib for Prevention of Colorectal Adenoma

Year: 2009

Type: article

Source: Gastroenterology

DOI: 10.1053/j.gastro.2009.02.045

Authors: Andrew T. Chan, Ann G. Zauber, Meier Hsu, Aurora Breazna, David J. Hunter, Rebecca B. Rosenstein, Craig J. Eagle, Ernest T. Hawk, Monica M.. Bertagnolli

Institutions: Brigham and Women's Hospital, Harvard University, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Pfizer (United States), The University of Texas MD Anderson Cancer Center

Language: English

Topic: Pharmacogenetics and Drug Metabolism

Subfield: Pharmacology

Field: Pharmacology, Toxicology and Pharmaceutics

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: American Association for Cancer Research, Damon Runyon Cancer Research Foundation, Pfizer, National Institutes of Health, National Cancer Institute

Awards: Dana Farber/ Harvard Cancer Center SPORE in Gastrointestinal Cancer, G1605461500, G1673005068, Inflammation and Colorectal Neoplasia, G306621025, G3289965895, G3754462075, Characterizing disease and treatment response in colon cancer chemoprevention, G7941870989, PHASE II CLINICAL TRIAL OF CELECOXIB (OR NSAID) FOR PREVENTION OF SPORADIC COLOR, Prospective Studies of Colorectal Adenoma, Cancer Center Support Grant

OpenAlex ID: W2112032502

FWCI: 5.38

Cites: 50

Cited by: 52

Related to: 10